Sometimes Jim Cramer tells a caller that he needs to do homework before he can make a decision on a stock. And he's not kidding.
Following is Cramer's research or homework on 3 health care stocks recently called to his attention by investors who watch the TV show.
On June 18th Leonard From Virginia called about Trius Therapeutics, a biotech spec pick that Cramer first talked about in May.
If you're long and went into the stock after Cramer's suggestion, he now says take some money off the table; "It is up 25% since my recommendation on May 3rd," he explained.
However, the Mad Money remains a buyer on a pullback, due to his belief that the company has a promising drug in the pipeline called Tedizolid, which may be effective in the treatment of serious skin infections. "The drug will be filed before the FDA later this year and I still think the company has a solid chance at approval in 2014," Cramer said.